Pyruvate kinase drugs for Transfusion-Dependent Beta Thalassemia

2 tracked Pyruvate kinase drugs in the Transfusion-Dependent Beta Thalassemia race. The class explanation lives on the Pyruvate kinase page; the full indication pipeline across every mechanism is on the Transfusion-Dependent Beta Thalassemia page.

1 approved / phase 41 Phase 3

Head-to-head evidence: Mitapivat vs Mitapivat (Aqvesme)

The roster

← all Pyruvate kinase drugs